Vanguard Personalized Indexing Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	+7,813	New	+$182K	﹤0.01%	1913

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Personalized Indexing Management's ARQT Position: Q2 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 7,813 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #1913 among its holdings.

272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Vanguard Personalized Indexing Management held 7,813 shares of Arcutis Biotherapeutics worth $205K as of Q2 2026.
Arcutis Biotherapeutics was a new Vanguard Personalized Indexing Management position in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1913 holding.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.